Anti-VEGF Versus Prompt Laser or Observation for Proliferative Sickle Cell Retinopathy (ALPS)

ClinicalTrials.gov ID: NCT07922460

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07922460. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to determine if anti-VEGF/anti-Ang2 therapy results in prevention of vitreous hemorrhage or retinal detachment as compared to localized scatter laser photocoagulation in patients with stage 3 Proliferative sickle retinopathy (PSR) and to determine if anti-VEGF therapy results in significant clearing of vitreous hemorrhage and faster improvement of visual acuity as compared to observation

Study identification

NCT ID: NCT07922460
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: University of Illinois Chicago; Other
Enrollment: 50 participants

Conditions and interventions

Conditions

Proliferative Sickle Cell Retinopathy

Interventions

Faricimab Injection for stage 3 or stage 4 Proliferative sickle cell eyes Drug
Vitrectomy Procedure
Laser photocoagulation Procedure

Drug · Procedure

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 1, 2026 (Estimated)
Primary completion: Dec 1, 2029 (Estimated)
Completion: Dec 1, 2030 (Estimated)
Last update posted: Nov 6, 2026

2026 – 2030

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
University of Illinois Chicago. Illinois Eye & Ear Infirmary, Department of Ophthalmology and Visual Sciences	Chicago	Illinois	60612	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07922460, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 6, 2026 · Synced Nov 15, 2026